Tirzepatide

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Tirzepatide: Comparison With Once-Weekly Semaglutide 2 mg

Tirzepatide compared with semaglutide 2 mg has not been studied.

US_cFAQ_TZP306_SEMAGLUTIDE_2MG
cFAQ
cFAQ
US_cFAQ_TZP306_SEMAGLUTIDE_2MG
en-US

Detailed Information

SURPASS-2 compared tirzepatide with once-weekly semaglutide 1 mg, the highest approved dose of semaglutide available at the time.1,2

Lilly has not conducted and are not currently conducting clinical studies comparing tirzepatide with once-weekly semaglutide 2 mg.2

References

1A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2). ClinicalTrials.gov identifier: NCT03987919. Updated March 11, 2021. Accessed March 23, 2021. https://clinicaltrials.gov/ct2/show/NCT03987919

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Lilly = Eli Lilly and Company

Date of Last Review: March 23, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical